Clinical neurogenetics: friedreich ataxia.

Abigail Collins

Journal: Neurologic clinics 2014;31(4):1095-120

PMID: 24176426

Full Text on Elsevier Science View on PubMed

Abstract

Friedreich ataxia is the most common autosomal recessive ataxia. It is a progressive neurodegenerative disorder, typically with onset before 20 years of age. Signs and symptoms include progressive ataxia, ascending weakness and ascending loss of vibration and joint position senses, pes cavus, scoliosis, cardiomyopathy, and arrhythmias. There are no disease-modifying medications to either slow or halt the progression of the disease, but research investigating therapies to increase endogenous frataxin production and decrease the downstream consequences of disrupted iron homeostasis is ongoing. Clinical trials of promising medications are underway, and the treatment era of Friedreich ataxia is beginning.

Address: Pediatrics and Neurology, Children's Hospital Colorado, University of Colorado, Denver, School of Medicine, 13123 East 16th Avenue, B155, Aurora, CO 80045, USA. Electronic address: [email protected].

DOI: 10.1016/j.ncl.2013.05.002

Link outs

Free resources

Medical:

https://medlineplus.gov/friedreichataxia.html

Other Literature Sources:

https://scite.ai/reports/24176426

Subscription / membership required

Full Text Sources:

MeSH Terms: Friedreich Ataxia, Humans, Iron-Binding Proteins, Frataxin